Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (201-210 of 721) with videos related to

Pageof 73
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2022
Radioiodine Ablation of Thyroid Remnants in Patients with Graves' OrbitopathyMichael Oeverhaus, Jana Koenen, Nikolaos Bechrakis, et al.
Endocrine|January 2, 2019
Thyroid stunning in radioiodine-131 therapy of benign thyroid diseasesChristian Happel, Wolfgang Tilman Kranert, Hanns Ackermann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2021
Factors predicting biochemical response and survival benefits following radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a reviewReyhaneh Manafi-Farid, Sara Harsini, Bahare Saidi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 2, 2023
Molecular Imaging Biomarkers in Cardiooncology: A View on Established Technologies and Future PerspectivesDavid Kersting, Ilektra-Antonia Mavroeidi, Stephan Settelmeier, et al.
Theranostics|July 21, 2020
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving <sup>177</sup>Lu-PSMA-617 Radioligand TherapyRobert Seifert, Konstantin Seitzer, Ken Herrmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
Strategy planning for turbulent times in nuclear medicine: Time to begin at the beginning?Rayjanah Allie, Irfan Kayani, Gopinath Gnanasegaran, et al.
EJNMMI Research|May 16, 2015
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapyConstantin Lapa, Rudolf A Werner, Christina Bluemel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomyHeiko Schöder, Ken Herrmann, Mithat Gönen, et al.
Cancers|July 9, 2022
Intra-Individual Comparison of <sup>124</sup>I-PET/CT and <sup>124</sup>I-PET/MR Hybrid Imaging of Patients with Resected Differentiated Thyroid Carcinoma: Aspects of Attenuation CorrectionHong Grafe, Maike E Lindemann, Manuel Weber, et al.
Theranostics|April 1, 2015
Radionuclide imaging of neurohormonal system of the heartXinyu Chen, Rudolf A Werner, Mehrbod S Javadi, et al.
Pageof 73

Showing results (201-210 of 721) with videos related to

Sort By:
Pageof 73
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2022
Radioiodine Ablation of Thyroid Remnants in Patients with Graves' OrbitopathyMichael Oeverhaus, Jana Koenen, Nikolaos Bechrakis, et al.
Endocrine|January 2, 2019
Thyroid stunning in radioiodine-131 therapy of benign thyroid diseasesChristian Happel, Wolfgang Tilman Kranert, Hanns Ackermann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2021
Factors predicting biochemical response and survival benefits following radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a reviewReyhaneh Manafi-Farid, Sara Harsini, Bahare Saidi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 2, 2023
Molecular Imaging Biomarkers in Cardiooncology: A View on Established Technologies and Future PerspectivesDavid Kersting, Ilektra-Antonia Mavroeidi, Stephan Settelmeier, et al.
Theranostics|July 21, 2020
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving <sup>177</sup>Lu-PSMA-617 Radioligand TherapyRobert Seifert, Konstantin Seitzer, Ken Herrmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2023
Strategy planning for turbulent times in nuclear medicine: Time to begin at the beginning?Rayjanah Allie, Irfan Kayani, Gopinath Gnanasegaran, et al.
EJNMMI Research|May 16, 2015
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapyConstantin Lapa, Rudolf A Werner, Christina Bluemel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomyHeiko Schöder, Ken Herrmann, Mithat Gönen, et al.
Cancers|July 9, 2022
Intra-Individual Comparison of <sup>124</sup>I-PET/CT and <sup>124</sup>I-PET/MR Hybrid Imaging of Patients with Resected Differentiated Thyroid Carcinoma: Aspects of Attenuation CorrectionHong Grafe, Maike E Lindemann, Manuel Weber, et al.
Theranostics|April 1, 2015
Radionuclide imaging of neurohormonal system of the heartXinyu Chen, Rudolf A Werner, Mehrbod S Javadi, et al.
Pageof 73